top-banner

METHODS AND TECHNOLOGIES

Non-invasive prenatal test

NON-INVASIVE PRENATAL TEST

A non-invasive prenatal test (NIPT) can detect the most common chromosomal abnormalities (trisomies 21, 18, and 13, and depending on the test method, sex chromosome aneuploidies as well as certain microdeletions) through modern high-throughput methods (next generation sequencing, NGS) performed on cell-free DNA of placental origin. This DNA is present in maternal blood or plasma during pregnancy. This significantly reduces the low procedural risk associated with invasive prenatal diagnostics for these specific questions. However, positive results should always be confirmed by amniocentesis, as false-positive and false-negative results are possible due to, for example, fetoplacental mosaicism.

All test methods require a sufficiently high fraction of placental DNA against the background of maternal DNA. The fetal fraction increases as pregnancy progresses but can be very low (< 4%) in some pregnant individuals. To ensure a sufficiently high fetal fraction for most individuals being tested, blood collection should not occur before the 10th week of pregnancy.

The tests currently available in Germany have been validated on high-risk populations, such as those with advanced maternal age or abnormal first-trimester screening results. For individuals without increased risk (e.g., pregnant individuals with unremarkable family histories or younger pregnant individuals), there is currently a lack of reliable data. Despite high sensitivity and specificity, false-positive and false-negative results can occur, which is why these tests are not currently considered diagnostic. Therefore, it is recommended that any abnormal findings be confirmed through diagnostic amniocentesis.

After genetic counseling (NIPT is regulated under the Genetic Diagnostics Act), 10-20 ml of blood are collected from the pregnant individual using specialized BCT tubes. After separating the blood plasma, the cell-free DNA from the placenta and mother is enriched and then quantitatively and/or qualitatively analyzed using NGS.

WAYS TO PARTNER WITH US

TarCET IVD Kits

CE-IVD kits containing reagents
for hereditary indications in
an easy-to-use kit form

Learn more

Technology Transfer

Out-of-the-box genetics workflow
from sequencing to reporting
for non-invasive prenatal testing

Learn more

Genetic Testing Laboratory

Your partner for
all genetic tests

Learn more

Contact Us

Please get in touch with us
for any questions, inquiries,
feedback, or with any
comments you might have.

Learn more

BLOG ARTICLES

February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th…

Read more

Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor…

Read more

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant…

Read more

Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact …

Read more

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc…

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of …

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access…

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is…

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti…

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati…

Read more

OUR NETWORK